SPDR S&P Pharmaceuticals ETF Rating $47.28 +0.02 (+0.04%) As of 01:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatingsShort InterestBuy This Stock SPDR S&P Pharmaceuticals ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.XPH Aggregate RatingModerate Buy 2.70Holdings in XPH have an aggregate rating of Moderate Buy based on 249 analyst ratings issued in the past year covering 25 companies (78.4% of the portfolio).XPH Aggregate Price Target$47.330.11% UpsideHigh Prediction$47.33Average Prediction$47.33Low Prediction$47.33Holdings in XPH have an aggregate price target of $47.33 and a range of $47.33 to $47.33 covering 25 companies (78.4% of the portfolio).XPH Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy9 Buy rating(s)Moderate Buy10 Moderate Buy rating(s)Hold5 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by SPDR S&P Pharmaceuticals ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 XPH Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings4.46%TARSTarsus Pharmaceuticals$58.18+0.0%1.8224 of 5 stars3.00$66.67 14.6%7Positive News4.28%ELANElanco Animal Health$18.450.0%2.8602 of 5 stars2.78$17.33 -6.0%94.04%VTRSViatris$10.57+1.5%1.9575 of 5 stars1.80$10.40 -1.6%53.82%JNJJohnson & Johnson$176.51+0.6%4.8507 of 5 stars2.65$176.29 -0.1%20Positive NewsEx-Dividend3.62%RPRXRoyalty Pharma$35.81+0.5%4.9889 of 5 stars3.33$48.00 34.1%3Positive News3.58%JAZZJazz Pharmaceuticals$127.66+1.2%4.7653 of 5 stars2.87$178.21 39.6%15Positive NewsAnalyst Forecast3.50%MRKMerck & Co., Inc.$83.87+0.8%4.9963 of 5 stars2.35$107.44 28.1%20Positive News3.48%PFEPfizer$24.73+0.5%4.8552 of 5 stars2.39$28.12 13.7%18Positive News3.43%CORTCorcept Therapeutics$69.46-0.2%4.7734 of 5 stars3.00$134.50 93.6%5Positive News3.41%AXSMAxsome Therapeutics$121.16-0.5%4.8306 of 5 stars3.07$178.00 46.9%15News CoveragePositive NewsInsider Trade3.23%BMYBristol Myers Squibb$46.94+0.1%4.795 of 5 stars2.24$56.38 20.1%21Positive News3.15%OGNOrganon & Co.$9.38+2.1%4.8083 of 5 stars2.50$18.00 92.0%6Positive News3.12%ZTSZoetis$155.92+0.7%4.9235 of 5 stars2.50$202.43 29.8%8Trending NewsAnalyst Revision2.94%ANIPANI Pharmaceuticals$92.66+0.1%3.2514 of 5 stars3.10$84.75 -8.5%10Insider Trade2.87%LLYEli Lilly and Company$731.59-0.1%4.9993 of 5 stars2.67$950.17 29.9%24Trending NewsAnalyst Upgrade2.86%PRGOPerrigo$23.74+1.1%4.9785 of 5 stars2.40$33.00 39.0%5Positive News2.83%HRMYHarmony Biosciences$37.21-2.0%4.6478 of 5 stars3.00$51.00 37.1%10Positive News2.71%LQDALiquidia Technologies$27.11-1.3%3.6152 of 5 stars3.00$32.11 18.4%102.70%XERSXeris Biopharma$7.71-2.5%3.5376 of 5 stars2.83$7.08 -8.1%62.58%PBHPrestige Consumer Healthcare$68.26+1.5%4.7461 of 5 stars2.50$93.33 36.7%6Positive News2.43%SUPNSupernus Pharmaceuticals$45.16-0.5%2.107 of 5 stars2.50$43.00 -4.8%4Analyst ForecastInsider Trade2.42%OCULOcular Therapeutix$12.27-2.0%4.0189 of 5 stars3.00$17.20 40.2%5Insider Trade2.41%PCRXPacira BioSciences$26.65-0.8%3.3314 of 5 stars2.71$30.83 15.7%7Positive News2.28%AMRXAmneal Pharmaceuticals$9.46-1.0%3.1116 of 5 stars3.00$11.60 22.7%5Positive NewsInsider Trade2.24%AMPHAmphastar Pharmaceuticals$30.49+0.8%3.3754 of 5 stars2.40$31.60 3.6%5Positive NewsAnalyst Forecast This page (NYSEARCA:XPH) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Pharmaceuticals ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access